OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer

OBJECTIVES: Erlotinib, the first generation of epidermoid growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recommended as an essential treatment in patients with non-small-cell lung cancer (NSCLC) with EGFR mutation. Although it has improved progression-free survival (PFS), over...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Feng, Zheng, Hanrui, Zhang, Pengfei, Hutton, David, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905764/
https://www.ncbi.nlm.nih.gov/pubmed/29654023
http://dx.doi.org/10.1136/bmjopen-2017-020128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905764/
https://www.ncbi.nlm.nih.gov/pubmed/29654023
http://dx.doi.org/10.1136/bmjopen-2017-020128

Ejemplares similares